Common Side Effects of Pegasys
Pegasys (peginterferon alfa-2a), used for hepatitis B and C, often causes flu-like symptoms including fatigue, headache, muscle pain, fever, chills, and joint pain. These affect over 50% of patients and typically start soon after injection, lasting a few hours to days.[1][2]
Skin reactions like redness, swelling, or itching at the injection site occur in about 25-50% of users. Nausea, vomiting, diarrhea, and loss of appetite are also frequent, sometimes leading to weight loss.[1]
Serious Side Effects and Risks
Mental health issues are a major concern: depression (up to 20%), anxiety, irritability, suicidal thoughts, or psychosis. Patients with a history of psychiatric disorders need close monitoring.[1][2]
Blood disorders include anemia (low red blood cells, 10-20%), neutropenia (low white cells, up to 25%), and thrombocytopenia (low platelets), which can increase infection or bleeding risk. Dose adjustments or discontinuation may be required.[1]
Other severe effects: thyroid problems (hypo- or hyperthyroidism), liver issues like autoimmune hepatitis, heart problems (arrhythmias), vision changes (retinopathy), and lung issues (pneumonitis). Rare cases involve stroke, heart attack, or severe allergic reactions.[2]
Side Effects by Treatment Duration and Patient Factors
Effects peak in the first few weeks and may lessen over time, but long-term use (up to 48 weeks) heightens risks like neuropathy or dental issues. Children on Pegasys report growth delays.[1]
Combining with ribavirin worsens anemia and birth defect risks—contraindicated in pregnancy. Elderly patients face higher infection risks; those with heart disease or autoimmune conditions should avoid it.[2]
Managing Side Effects
Doctors recommend acetaminophen for flu-like symptoms, starting at lower doses, and premedicating before injections. Regular blood tests monitor blood counts and liver function. Report mood changes immediately.[1] Stopping treatment resolves most effects, though some like thyroid issues persist.
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5215lbl.pdf
[2] https://www.pegasys.com/